Abstract
Adenosine is a ubiquitous signaling molecule, with widespread activity across all organ systems. There is evidence that adenosine regulation is a significant factor in traumatic brain injury (TBI) onset, recovery, and outcome, and a growing body of experimental work examining the therapeutic potential of adenosine neuromodulation in the treatment of TBI. In the central nervous system (CNS), adenosine (dys)regulation has been demonstrated following TBI, and correlated to several TBI pathologies, including impaired cerebral hemodynamics, anaerobic metabolism, and inflammation. In addition to acute pathologies, adenosine function has been implicated in TBI comorbidities, such as cognitive deficits, psychiatric function, and post-traumatic epilepsy. This review presents studies in TBI as well as adenosine-related mechanisms in co-morbidities of and unfavorable outcomes resulting from TBI. While the exact role of the adenosine system following TBI remains unclear, there is increasing evidence that a thorough understanding of adenosine signaling will be critical to the development of diagnostic and therapeutic tools for the treatment of TBI.
Keywords: Adenosine deaminase, adenosine kinase, nucleotidase, nucleoside transport, caffeine, comorbidity
Current Neuropharmacology
Title: Adenosine Neuromodulation and Traumatic Brain Injury
Volume: 7 Issue: 3
Author(s): T. A. Lusardi
Affiliation:
Keywords: Adenosine deaminase, adenosine kinase, nucleotidase, nucleoside transport, caffeine, comorbidity
Abstract: Adenosine is a ubiquitous signaling molecule, with widespread activity across all organ systems. There is evidence that adenosine regulation is a significant factor in traumatic brain injury (TBI) onset, recovery, and outcome, and a growing body of experimental work examining the therapeutic potential of adenosine neuromodulation in the treatment of TBI. In the central nervous system (CNS), adenosine (dys)regulation has been demonstrated following TBI, and correlated to several TBI pathologies, including impaired cerebral hemodynamics, anaerobic metabolism, and inflammation. In addition to acute pathologies, adenosine function has been implicated in TBI comorbidities, such as cognitive deficits, psychiatric function, and post-traumatic epilepsy. This review presents studies in TBI as well as adenosine-related mechanisms in co-morbidities of and unfavorable outcomes resulting from TBI. While the exact role of the adenosine system following TBI remains unclear, there is increasing evidence that a thorough understanding of adenosine signaling will be critical to the development of diagnostic and therapeutic tools for the treatment of TBI.
Export Options
About this article
Cite this article as:
Lusardi A. T., Adenosine Neuromodulation and Traumatic Brain Injury, Current Neuropharmacology 2009; 7 (3) . https://dx.doi.org/10.2174/157015909789152137
DOI https://dx.doi.org/10.2174/157015909789152137 |
Print ISSN 1570-159X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6190 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Executive Functioning in Alcohol Use Studies: A Brief Review of Findings and Challenges in Assessment
Current Drug Abuse Reviews Anti-Diabetic Compounds and their Patent Information: An Update
Recent Patents on Inflammation & Allergy Drug Discovery Are the Extracelluar Pathways a Conduit for the Delivery of Therapeutics to the Brain?
Current Pharmaceutical Design Diacerein-Thymol Prodrug: <i>In Vivo</i> Release and Pharmacological Screening in Experimental Models of Osteoarthritis in Wistar Rats
Inflammation & Allergy - Drug Targets (Discontinued) Transient Receptor Potential Vanilloid 1 Channel Modulation: A Novel Approach to Pain Therapy
Current Bioactive Compounds Renin-Angiotensin-Aldosterone System: A Current Drug Target for the Management of Neuropathic Pain
Current Drug Targets Editorial [Hot Topic:Active and Passive Aβ-Immunotherapy: Preclinical and Clinical Studies and Future Directions: Part I (Guest Editors: Michael G. Agadjanyan and David H. Cribbs)]
CNS & Neurological Disorders - Drug Targets Toll-Like Receptors: Sensor Molecules for Detecting Damage to the Nervous System
Current Protein & Peptide Science Radiolabeled Imaging Probes Targeting Angiogenesis for Personalized Medicine
Current Pharmaceutical Design Curcumin: Powerful Immunomodulator from Turmeric
Current Immunology Reviews (Discontinued) Potentials of ES Cell Therapy in Neurodegenerative Diseases
Current Pharmaceutical Design Rac-1 as a New Therapeutic Target in Cerebro- and Cardio-Vascular Diseases
Current Drug Targets Brain Drug Delivery Systems for the Stroke Intervention and Recovery
Current Pharmaceutical Design Atomoxetine Protects Against NMDA Receptor-mediated Hippocampal Neuronal Death Following Transient Global Cerebral Ischemia
Current Neurovascular Research Subject Index to Volume 4
Current Molecular Medicine Blocking Leukocyte Rolling: Does it have a Role in Disease Prevention?
Vascular Disease Prevention (Discontinued) COX-2 in Brain and Spinal Cord - Implications for Therapeutic Use.
Current Medicinal Chemistry Neuroinflammation is Associated with Brain Extracellular TAU-Protein Release After Spontaneous Subarachnoid Hemorrhage
Current Drug Targets Metabolic Fate of Endocannabinoids
Current Neuropharmacology Redox mechanisms in pathological angiogenesis in the retina: roles for NADPH oxidase
Current Pharmaceutical Design